[Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome]
Marco Tubaro1, Giulia Falaschi1, Furio Colivicchi1
1U.O.C. Cardiologia, P.O. San Filippo Neri, ASL Roma 1, Roma.
Insights
Managing antithrombotic therapy for atrial fibrillation and acute coronary syndrome patients balances ischemic and bleeding risks. Combination therapy with anticoagulants and antiplatelets is supported, but optimal choices are still debated.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis Research
Background:
- Patients with atrial fibrillation and acute coronary syndrome face complex treatment challenges.
- Balancing cardiac ischemic risk, thromboembolic risk, and bleeding risk is crucial.
Purpose of the Study:
- To review current evidence on antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome.
- To highlight ongoing controversies and areas for future research in optimizing this therapy.
Main Methods:
- Analysis of data from numerous trials and meta-analyses.
- Review of completed and ongoing clinical trials addressing therapeutic choices.
Main Results:
- Combination therapy with oral anticoagulants (vitamin K antagonists or direct oral anticoagulants) and antiplatelet agents (aspirin, clopidogrel) is currently supported.
- Significant controversies remain regarding optimal agent selection, dosage, and duration of dual antiplatelet therapy.
Conclusions:
- Antithrombotic therapy in this patient population requires careful consideration of multiple risk factors.
- Further research is needed to define optimal strategies for anticoagulant and antiplatelet selection and duration to improve patient outcomes.
Abstract:
Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome is a difficult challenge because of the need of taking into consideration three different issues: the cardiac ischemic risk related to coronary artery disease and its treatment with angioplasty and stenting; the thromboembolic risk associated with atrial fibrillation; and the hemorrhagic risk related to the combined use of antiplatelet therapy (with one or two agents) and oral anticoagulant therapy.Data from many trials and meta-analyses currently support a combination therapy with oral anticoagulants (vitamin K antagonists or direct oral anticoagulants) and antiplatelet agents (aspirin and clopidogrel in dual or single antiplatelet therapy).Recently completed and ongoing trials aim to tackle the still controversial issues of this therapy: the choice of the anticoagulant agent and its dosage; the choice of the antiplatelet agent; the use of single or dual antiplatelet therapy and its duration.
Related Concept Videos
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome V: Nursing Management
Acute Coronary Syndrome III: Diagnostic Studies
Acute Coronary Syndrome IV: Interprofessional Care
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...


